Evaluation of isocitrate dehydrogenase mutation in 2021 world health organization classification grade 3 and 4 glioma adult-type diffuse gliomas with 18F-fluoromisonidazole PET
ConclusionPET using18F-FMISO and ADC might provide a valuable tool for differentiating betweenIDH mutation status of 2021 WHO classification grade 3 and 4 adult-type diffuse gliomas.
Source: Japanese Journal of Radiology - Category: Radiology Source Type: research
More News: Brain Tumor | Glioma | International Medicine & Public Health | Japan Health | Radiology | Study | WHO